The Research

Meet a Research Team that’s driving towards the cure:

Patrick Reynolds, M.D., PhD

Dr1
Dr. Reynolds received his BA in Biology from The University of Texas at Austin, his MD from UT Southwestern Medical School in Dallas, TX, his PhD (Cell Biology) from UT Austin, and his pediatrics training at the National Naval Medical Center. His postdoctoral fellowship was in cancer immunology at UT Southwestern Medical School, Dallas, TX. His areas of research interest are: 1) retinoids as tumor-selective differentiation or cytotoxic agents, 2) mechanisms of drug resistance and drugs to modulate resistance in childhood and adult cancers, 3) development of novel preclinical testing models for childhood cancer drug development, and 4) clinical trials testing novel therapeutic approaches for cancer.

Barry Maurer, M.D., PhD

Dr2
Dr. Maurer is a board-certified pediatric oncologist who received his PhD degree from Caltech and his MD from Wayne State University, Detroit. His pediatric oncology training was done at the world-renowned Fred Hutchinson Cancer Center in Seattle. Before being recruited to the Cancer Center at Texas Tech University Health Sciences Center, Lubbock, Dr. Maurer served for ten years as an Attending Physician at the Children’s Hospital Los Angeles (CHLA), and as a moonlighting physician at the City of Hope Cancer Center, Duarte CA, all while maintaining an NCI-funded cancer research laboratory at the University of Southern California.

Min H Kang, PharmD

Dr3
Dr. Kang joined Texas Tech University Health Sciences Center in 2008 as an assistant professor of Cell Biology and Biochemistry. She received her BS in Pharmacy from Chungbuk National University in South Korea and her Doctor of Pharmacy from University of Colorado at Denver. She continued her postdoctoral fellowship training at the National Cancer Institute, National Institutes of Health, Bethesda, MD. Her main goal of research is to develop new treatment modalities for pediatric cancer.

 

 


VIDEO:

 

Watch Dr Barry Maurer explain the approach that has led this team to a new, breakthrough treatment – a drug that is proving effective with a variety of cancers.